Current immunotherapy of multiple sclerosis a review of clinical experience

Clinical Immunotherapeutics

Volumn 5, Issue , 1996, Pages 12-21

  Martin, Roland ^a   Hohlfeld, Reinhard ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLATIRAMER; GLUCOCORTICOID; METHYLPREDNISOLONE;

CONFERENCE PAPER; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029974260     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Paty D, Wiloughby E, Whilaker J. Assessing the outcome of experimental therapies in multiple sclerosis patients. In: Ruclick RA, Goodkin DE, editors. Treatment of multiple sclerosis - trial design, results and future perspectives. London: Springer, 1992:47-90
2. Myers L. Treatment of multiple sclerosis with ACTH and corticosteroids. In: Rudick RA, Goodkin DE, editors. Treatment of multiple sclerosis - trial design, results and future perspectives. London: Springer, 1992: 135-56
3. Barkhof F, Frequin STFM, Hommes OR, et al. A correlative triad of gadolinium-DTPA, MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992; 42: 63-7
4. Barnes MP, Bateman DE, Cleland PC, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985; 48: 157-9
5. Kesselring J, Miller DH, MacManus DO, et al. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 1989; 52: 14-7
6. Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 1988; 51: 285-7
7. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450-3
8. Milligan NM, Newcombe R. Compson DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: I. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-6
9. Thompson AJ, Kennard C. Swash M. et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39: 969-71
10. Beck RW. Cleary PA, Anderson MM, et al. and the Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. New Engl J Med 1992; 326: 581-8
11. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. New Engl J Med 1993: 329: 1764-9
12. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine in multiple sclerosis. Lancet 1991: 338: 1051-5
13. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988: 2: 179-83
14. Goodin DS. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology 1991 : 41:980-5
15. Hauser SL, Dawson DM, Lehrich JR. et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophospamide, plasma exchange, and ACTH. New Engl J Med 1983: 308: 173-80
16. Hommes OR, Lamers KJB, Reekers P. Effect of immunosuppression on thé course of chronic progressive multiple sclerosis. J Neurol 1980: 223: 177-90
17. Weiner HL, Mackin GA. Orav EJ, et al. Intermittent cyelophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Coopérative Multiple Sclerosis Treatment Group. Neurology 1993: 43: 910-8
18. The Canadian Co-operative Multiple Sclerosis Study Group. The Canadian co-operative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-6
19. Mackin GA, Dawson DM, Hafler DA, et al. Treatment of multiple sclerosis with cyclophosphamide. In: Rudick RA, Goodkin DE, editors. Treatment of multiple sclerosis - trial design, results and future perspectives. London: Springer. 1992: 199216
20. Wolinsky JS. Treatment of multiple sclerosis with cyclosporin A. In: Rudick RA, Goodkin DE, editors. Treatment of multiple sclerosis - trial design, results and future perspectives. London: Springer. 1992: 217-32
21. Kappos L. Patzold U. Dommasch D, et al. Cyclosporine versus azathioprine in long-term treatment of multiple sclerosis results of the German multicenter study. Ann Neurol 1988: 23: 56-63
22. Rudge P, Koetsier JC, Merlin J. et al. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989: 52: 559-65
23. Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990:27:591-605
24. PanitchHS. Hirsch RL. SchindlerJ. et al. Treatment of multiple sclerosis with gamma Interferon: exacerbations associated with activation of the immune system. Neurology 1987: 37: 1097-1102
25. Jacobs L, Munschauer F. Treatment of multiple sclerosis with interferons. In: Rudick RA. Goodkin DE, editors. Treatment of multiple sclerosis -trial design, results and future perspectives. London: Springer, 1992: 233-50
26. The IFNB Multiple Sclerosis Study Group. Interferon bela-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
27. Paty DW, Li DKB, the UBC MS/MRI Study Group, et al. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. IL MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7
28. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon lb in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995: 45: 1277-85
29. Bornstein MB, Johnson KP. Treatment of multiple sclerosis with Copolymer I. In: Rudick RA, Goodkin DE, editors. Treatment of multiple sclerosis - trial design, results and future perspectives. London: Springer. 1992: 173-98
30. Johnson KP. Brooks BR. Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, doubleblind, placebo-controlled trial. Neurology 1995:45: 1268-76